Shopping Cart
Remove All
Your shopping cart is currently empty
Varisacumab
Copy Product Info
😃Good
Catalog No. T80877Cas No. 1610010-60-0
Alias R 84 (antibody), GNR-011
Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes.
Varisacumab
Varisacumab
Copy Product Info😃Good
Catalog No. T80877Alias R 84 (antibody), GNR-011Cas No. 1610010-60-0
Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes. |
| Targets&IC50 | VEGFA:< 7 nM (Kd) |
| In vitro | In binding assays with human VEGF165, Varisacumab (r84) exhibited high affinity with an EC50 of 0.288 nM and inhibited VEGF-induced tube formation in HUVEC models [1]. |
| In vivo | In human breast cancer xenograft models, systemic administration of Varisacumab (r84) significantly reduced tumor volume and microvascular density [1]. |
| Synonyms | R 84 (antibody), GNR-011 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | VEGF-A |
| Cas No. | 1610010-60-0 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Varisacumab | purchase Varisacumab | Varisacumab cost | order Varisacumab | Varisacumab in vivo | Varisacumab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.